GeneOne Life Science Inc. (011000)

Overview

GeneOne Life Science, Inc., originally established as VGX International Inc. in 1976, underwent a name change in April 2014 and is now recognized as a significant entity in the biopharmaceutical industry. Headquartered in Seoul, South Korea, this company is actively engaged in the research and development as well as contract manufacturing of nucleic acid-based biopharmaceuticals. Their efforts are primarily focused on advancing a diverse pipeline of small molecule and nucleic acid vaccines targeting a range of diseases, including infectious diseases and conditions chronic in nature. Additionally, GeneOne Life Science, Inc. also specializes in the cGMP (current Good Manufacturing Practice) production of nucleic acid-based products, such as DNA plasmids and mRNA, highlighting their commitment to quality and regulatory compliance in biopharmaceutical manufacturing.

Products and Services

Small Molecule Pipeline:

• GLS-1027: Currently in Phase I clinical trials, this small molecule is under investigation for the treatment of nephropathy and inflammatory diseases.
• GLS-1200: This candidate is in Phase II clinical trial, aiming to treat Rhinosinusitis. Additionally, it's being explored for its potential in treating COVID-19 alongside GLS-1027 in a separate Phase II clinical trial.

Nucleic Acid Vaccines:

• GLS-3000 mRNA: Under a feasible study, this mRNA vaccine targets SARS-CoV-2, the virus responsible for COVID-19.
• GLS-5310 DNA: Currently in phase 2, this DNA vaccine is another effort against SARS-CoV-2.
• GLS-5100: This pre-clinical stage DNA vaccine is designed for the prevention of herpes zoster, commonly known as shingles.
• GLS-5140: Also in the pre-clinical stage, this vaccine aims at the prophylaxis treatment of SFTS (Severe Fever with Thrombocytopenia Syndrome).
• GLS-5300: In Phase II clinical trials for the prevention of MERS (Middle East Respiratory Syndrome).
• GLS-5700: This vaccine is in Phase I clinical trial targeting the Zika virus.
• GLS-6150: Aimed at hepatitis C re-infection prophylaxis, this candidate is in Phase I clinical trial.
• GLS-6100: Currently in pre-clinical stage, targeting hepatitis C prophylaxis.

Discovery and optimization stage pipeline:

• GLS-7000: Focused on the treatment of breast cancer.
• GLS-7100: Aimed at treating hemophilia A.
• GLS-8000: For the prevention of chronic hepatitis B.
• GLS-8100: Targeting rheumatoid arthritis for treatment.

cGMP Production of Nucleic Acid-Based Products: GeneOne Life Science, Inc. is involved in the cGMP production, focusing on DNA plasmids and mRNA, which are critical components in the development and manufacturing of gene therapies and vaccines.